Fexofenadine is named as an intervention in 2 current clinical trials in our China and USA registers. 2 are recruiting patients now. All registered phases are Phase 3. The sponsor with the most trials is Sanofi (1). The most-studied condition is Pruritus.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
NCT05263206 · ClinicalTrials.gov ↗ · Pruritus
|
Phase 3 | Recruiting | Sanofi | USA, China |
|
The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction
NCT07381803 · ClinicalTrials.gov ↗ · Zhejiang University
|
Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
12 single-substance products containing Fexofenadine on the HPRA medicines list.
No entry for Fexofenadine in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Sanofi | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and USA registers name Fexofenadine as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Sanofi (1) and Second Affiliated Hospital, Zhejiang University, School of Medicine (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 12 single-substance products containing Fexofenadine, for example Fexo Allergy Relief 120 mg film-coated tablets (Rowa Pharmaceuticals Limited,). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Fexofenadine has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Fexofenadine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Fexofenadine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Fexofenadine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.